UK markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1700+0.0500 (+4.46%)
At close: 04:00PM EDT
1.1800 +0.01 (+0.85%)
After hours: 07:59PM EDT
Sign in to post a message.
  • j
    jwg1234556789
    The market potential for Z is incredible. Billions of dollars in sales potential, although I see ATOS being bought up long before Z gets to market.
  • A
    Anonymous
    Research on Z-Endoxifen, Tamoxifen and letrozole:

    Search PMC Full-Text Archive

    Advanced Search User Guide
    Journal List Breast Cancer Res v.22; 2020 PMC7238733
    Logo of brcnres
    Breast Cancer Res. 2020; 22: 51.
    Published online 2020 May 19. doi: 10.1186/s13058-020-01286-7
    PMCID: PMC7238733
    PMID: 32430040

    Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

    Swaathi Jayaraman,1 Xiaonan Hou,1 Mary J. Kuffel,1 Vera J. Suman,2 Tanya L. Hoskin,2 Kathryn E. Reinicke,1 David G. Monroe,3 Krishna R. Kalari,2 Xiaojia Tang,2 Megan A. Zeldenrust,1 Jingfei Cheng,1 Elizabeth S. Bruinsma,3 Sarah A. Buhrow,1 Renee M. McGovern,1 Stephanie L. Safgren,1 Chad A. Walden,1 Jodi M. Carter,4 Joel M. Reid,1 James N. Ingle,1 Matthew M. Ames,1 John R. Hawse,3 and Matthew P. Goetzcorresponding author1,5
    Author information Article notes Copyright and License information Disclaimer
    This article has been cited by other articles in PMC.
    Associated Data
    Supplementary Materials
    Data Availability Statement
    Go to:
    Abstract
    Background

    The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), as well as with tamoxifen, fulvestrant, exemestane, and exemestane plus everolimus in a letrozole-resistant MCF7 model (MCF7LR).

    Methods
    MCF7AC1 tumor-bearing mice were randomized to control (no drug), letrozole (10 μg/day), tamoxifen (500 μg/day), or Z-endoxifen (25 and 75 mg/kg). Treatment in the letrozole arm was continued until resistance developed. MCF7LR tumor-bearing mice were then randomized to Z-endoxifen (50 mg/kg) or tamoxifen for 4 weeks and tumors harvested for microarray and immunohistochemistry analysis. The antitumor activity of Z-endoxifen in the MCF7LR tumors was further compared in a second in vivo study with exemestane, exemestane plus everolimus, and fulvestrant.

    Results
    In the MCF7AC1 tumors, both Z-endoxifen doses were significantly superior to control and tamoxifen in reducing tumor volumes at 4 weeks. Additionally, the 75 mg/kg Z-endoxifen dose was additionally superior to letrozole. Prolonged letrozole exposure resulted in resistance at 25 weeks. In MCF7LR tumor-bearing mice, Z-endoxifen significantly reduced tumor volumes compared to tamoxifen, letrozole, and exemestane, with no significant differences compared to exemestane plus everolimus and fulvestrant. Additionally, compared to tamoxifen, Z-endoxifen markedly inhibited ERα target genes, Ki67 and Akt expression in vivo.

    Conclusion
    In endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen results in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy. These data support the ongoing development of Z-endoxifen.

    Anonymous A
  • A
    Anonymous
    Cash value per share-$1.06, no debt.
    SP can launch from here to $8 and more.
    Part III on AT-H201 clinical trail finishing in 3 Q (Covid-19 treatment)
    IND submission for Endoxifen to FDA on P2 clinical trial in 2nd Q (breast cancel treatment)
    Reminder, Endoxifen is a big deal in market size to replace Chemo on
    reducing tumor cell activities/breast cancel density
    Add your positions now, because SP is not going under $1

    Anonymous A
  • H
    How Much?
    nice to see ATOS back on the move. can't wait for them to begin p2. that should bring in new money and if the trial is stopped early for good results, there is no stopping it. glad i held and added along the way. go ATOS. but to be honest, it was a hard to hold and keep the faith. DD makes all the difference.
  • A
    Anonymous
    Some Huge blocks traded before closing
    2,116,709 shares changed hands after hours just in 10 minutes after closing
    Heavy volume on uptrend lately
    positive signal for big action next week
    Enjoy the ride my friends!

    Anonymous A
  • H
    HelloAmericanChives
    under $1,buy buy buy
    EZ MONEY!!
  • S
    Sashk
    the 30 day fda deadline nod should be right around corner. if they give the go-ahead, which they will .we should see big buyer comes in!
  • S
    Sashk
    . hope all is well. look for some movement on ATOS on or about June 30th. that should be the deadline for FDA to give or not give the okay for the start of p2… so get ready and load up .. thjs thing will fly ..
  • J
    Jazzy
    IND approval soon?
  • a
    alan
    Roy ! can't forget. it's still a risky stock ! it's still. has quite a ways to go ! there are some factors going for us! and a lot not ! that equates to. high risk !!! 🤔👍🤠
  • a
    alan
    pie ! is this girl. portugsese ? northern Europe ? do you know ??
  • J
    Jazzy
    Nice gains this week. Keep it up ATOS!
  • C
    CERISIER
    New trader watchlist was published by these guys and it featured ATOS. (http://traderspot.club)
  • a
    alan
    it seems as tho it's going up !!! 😂👍🤠
  • j
    john
    Realistically when will this go back to 4 where I bought it
  • a
    alan
    ANOTHER FEW DAYS ! 👍👍👍😁😁😁🤠
  • H
    HEGENBART
    The pick that was just sent out by (http://traderspot.club) is already up yuge! Check it out!
  • a
    alan
    this price is being hiked up like the queens. depends ! how high can we go ??
  • a
    alan
    I posted two days ago !
  • S
    Sashk
    altight atos did p2 in australia and they stopped it early for good result. the fda said to do a p2 in the usa but this time compare it to the standard chemotherapy treatment administered when cancer is discovered. so as of now, if they discover breast cancer they do chemotherapy and eventually surgery. atos is looking to substitute chemotherapy with a pill. I am simplifying it a lot. so if the results are the same as what they found in Australia, ATOS can become an alternative to chemotherapy or the new standard of care. they should provide an update on the trial in Q3. ..so tell me 10 is too low...25$ is what we looking in 6 months